Monday, 02 May 2011 | Inhalation devices for Japan
PARI donates mobile inhalation devices for Japanese earthquake and tsunami victims
Thursday, 02 December 2010 | Nebulised antibiotic: decreased exacerbations and better quality of life for patients with bronchiectasis
The largest long-term study on an inhaled antibiotic to date demonstrated that the therapy helps patients in multiple ways
Thursday, 18 November 2010 | VORTEX Snug, hygienically safe, and fun to use:
The new child masks for VORTEX holding chambers
Tuesday, 23 November 2010 | Pilot study with MucoClear 6% in bronchiectasis: 12% of patients find improvements "life-changing“
Current study with 41 patients was presented during the annual congress of the European Respiratory Society
Tuesday, 23 November 2010 | Patients with bronchiectasis judge nebulised hypertonic saline as very useful
How useful are the different therapies to patients with bronchiectasis? A group of British physicians asked that patient-centered question to 36 of their bronchiectasis patients. They were interested in knowing patients’...
Wednesday, 24 November 2010 | Sopranos find: Nebulised saline makes singing more effortless
The influence of dry vocal cords on the intonation effort was investigated in 34 professional singers.
Thursday, 05 August 2010 | Cystic fibrosis: Does hypertonic saline improve nutritional status?
Results were presented at this year’s European Cystic Fibrosis Conference from a study in which BMI had significantly increased for 14 cystic fibrosis patients after inhaling hypertonic saline for at least 18 months.
Monday, 19 July 2010 | PARI SINUS and dornase alfa: an efficient tandem team in treating chronic rhinosinusitis
Chronic rhinosinusitis is a complex condition that is quite common and considerably compromises the quality of life in cystic fibrosis patients. In a study conducted with the mucolytic drug dornase alfa via PARI SINUS, cystic...
Monday, 21 June 2010 | PARI LC SPRINT: nebuliser of choice for clinical trials with inhaled antibiotic
The main advantage of inhaled antibiotic therapy is that the drug directly reaches the site of action and reduces adverse events for the entire organism. Recent results from ongoing clinical trials with ciprofloxacin – an...
